These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36729885)

  • 21. Coordinating Outpatient Care for Pregnant and Postpartum Women with Opioid Use Disorder: Implications from the COACHH Program.
    Hodgins FE; Lang JM; Malseptic GG; Melby LH; Connolly KA
    Matern Child Health J; 2019 May; 23(5):585-591. PubMed ID: 30604105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine/naloxone.
    Petrich M; Battin M; Walker E; Brown M; Abdelwahab M; Ma'ayeh M; Rood KM
    J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10481-10486. PubMed ID: 36202398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
    Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
    Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming Barriers: Individual Experiences Obtaining Medication-Assisted Treatment for Opioid Use Disorder.
    Scorsone KL; Haozous EA; Hayes L; Cox KJ
    Qual Health Res; 2020 Nov; 30(13):2103-2117. PubMed ID: 32691670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled trial of an intervention to reduce stigma toward people with opioid use disorder among primary care clinicians.
    Hooker SA; Crain AL; LaFrance AB; Kane S; Fokuo JK; Bart G; Rossom RC
    Addict Sci Clin Pract; 2023 Feb; 18(1):10. PubMed ID: 36774521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Substance Use, Recovery, and Non-Drug-Related Online Community Participation on the Risk of a Use Episode During Remission From Opioid Use Disorder: Longitudinal Observational Study.
    Naserianhanzaei E; Koschate-Reis M
    J Med Internet Res; 2022 Aug; 24(8):e36555. PubMed ID: 35994333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: Associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year.
    Pro G; Utter J; Haberstroh S; Baldwin JA
    Drug Alcohol Depend; 2020 Apr; 209():107952. PubMed ID: 32172130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid Use Disorder and Perinatal Outcomes.
    Piske M; Homayra F; Min JE; Zhou H; Marchand C; Mead A; Ng J; Woolner M; Nosyk B
    Pediatrics; 2021 Oct; 148(4):. PubMed ID: 34479983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a Nurse-Led Program for Rural Pregnant Women With Opioid Use Disorder to Improve Maternal-Neonatal Outcomes.
    Paterno MT; Jablonski L; Klepacki A; Friedmann PD
    J Obstet Gynecol Neonatal Nurs; 2019 Sep; 48(5):495-506. PubMed ID: 31374181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trending the evidence on opioid use disorder (OUD) continuum of care among rural American Indian/Alaskan Native (AI/AN) tribes: A systematic scoping review.
    Mpofu E; Ingman S; Matthews-Juarez P; Rivera-Torres S; Juarez PD
    Addict Behav; 2021 Mar; 114():106743. PubMed ID: 33359980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does co-location of medication assisted treatment and prenatal care for women with opioid use disorder increase pregnancy planning, length of interpregnancy interval, and postpartum contraceptive uptake?
    Collier KW; MacAfee LK; Kenny BM; Meyer MC
    J Subst Abuse Treat; 2019 Mar; 98():73-77. PubMed ID: 30665607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
    Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
    Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder.
    Wilder C; Lewis D; Winhusen T
    Drug Alcohol Depend; 2015 Apr; 149():225-31. PubMed ID: 25735465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Criminal Statutes for Opioid Use Disorder With Prevalence and Treatment Among Pregnant Women With Commercial Insurance in the United States.
    Gressler LE; Shah S; Shaya FT
    JAMA Netw Open; 2019 Mar; 2(3):e190338. PubMed ID: 30848807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postpartum and addiction recovery of women in opioid use disorder treatment: A qualitative study.
    Martin CE; Almeida T; Thakkar B; Kimbrough T
    Subst Abus; 2022; 43(1):389-396. PubMed ID: 34214405
    [No Abstract]   [Full Text] [Related]  

  • 38. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.
    Campbell CI; Saxon AJ; Boudreau DM; Wartko PD; Bobb JF; Lee AK; Matthews AG; McCormack J; Liu DS; Addis M; Altschuler A; Samet JH; LaBelle CT; Arnsten J; Caldeiro RM; Borst DT; Stotts AL; Braciszewski JM; Szapocznik J; Bart G; Schwartz RP; McNeely J; Liebschutz JM; Tsui JI; Merrill JO; Glass JE; Lapham GT; Murphy SM; Weinstein ZM; Yarborough BJH; Bradley KA
    Addict Sci Clin Pract; 2021 Jan; 16(1):9. PubMed ID: 33517894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medications for opioid use disorder among pregnant women referred by criminal justice agencies before and after Medicaid expansion: A retrospective study of admissions to treatment centers in the United States.
    Winkelman TNA; Ford BR; Shlafer RJ; McWilliams A; Admon LK; Patrick SW
    PLoS Med; 2020 May; 17(5):e1003119. PubMed ID: 32421717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.